<DOC>
	<DOCNO>NCT00538057</DOCNO>
	<brief_summary>A combination corticosteroid GW685698X long-acting ß2-agonist GW642444M develop daily administration maintenance treatment asthma COPD . GW642444M GW685698X simultaneously co-administered single device compare GW642444M GW685698X administer separately order determine whether co-administration affect safety , tolerability , pharmacodynamic and/or pharmacokinetics either compound .</brief_summary>
	<brief_title>Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy adult age 18 60 year . Male subject female subject non child bear potential . Body weight least 50 kg BMI within range 1931 kg/m2 inclusive . No significant abnormality ECG screening . FEV1 least 90 % predict FEV1 / FVC ratio least 0.7 screen . Current nonsmoker use tobacco product 12 month period precede screen visit pack history equal le 5 pack year . Exclusion criterion : Systolic blood pressure 145 mmHg diastolic pressure 85 mmHg unless Investigator confirm satisfactory age . The subject treat diagnosed depression within six month screen history significant psychiatric illness . Subjects suffer upper low respiratory tract infection within 4 week screen visit . Liver function test ( AST , ALT ALP ) great 1.5 upper limit laboratory reference range . History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation . History milk protein allergy . The subject take prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator Sponsor medication interfere study procedure compromise subject safety . The subject take oral corticosteroid le 8 week screen visit The subject take inhaled , intranasal topical steroid le 4 week screen visit History alcohol/drug abuse dependence within 12 month study . The subject participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Exposure four new chemical entity within 12 month prior first dose day . The subject donate unit ( 450mL ) blood within previous 16 week intend donate within 16 week complete study . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . The subject test positive HIV antibody . The subject positive prestudy urine drug screen . Positive CO alcohol breath test screen admission Unit . History adverse reaction include immediate delay hypersensitivity ICS , ß2agonist sympathomimetic drug . gefitinib erlotinib ) permit . Use bevacizumab must end least 40 day prior date first dose study drug . Any anticancer therapy ( surgery , tumor embolization , chemotherapy , radiation therapy , immunotherapy , biological therapy , hormonal therapy ) currently within 14 day prior date first dose study drug . Any ongoing toxicity prior anticancer therapy great Grade 1 and/or progress severity . Known immediate delay hypersensitivity reaction idiosyncracy drug chemically relate pazopanib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Healthy volunteer</keyword>
</DOC>